Human Immunodeficiency Virus | Current Treatment | EU5 | 2016

The HIV therapy market is growing as a result of the uptake of new premium-priced antiretroviral agents, particularly the latest single-tablet regimens (STRs) with improved side-effect profiles that place an emphasis on safety and tolerability. Our Current Treatment content provides deep insights drawn from a survey of 253 infectious disease specialists, internal medicine physicians, and general practitioners in the EU5 regarding the current and anticipated use of HIV regimens, including the recently approved STR Genvoya (elvitegravir/emtricitabine/tenofovir alafenamide/cobicistat), by capturing patient- and market-share data, current prescribing trends, and anticipated changes in prescribing and treatment behavior.

Login to access report